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234Objective: Meta-analysis of small, randomized, placebo-controlled trials demonstrated efficacy and safety of
aprotinin. After highly publicized retrospective studies and the early stopping of the Blood Conservation Using
Antifibrinolytics in a Randomized Trial (BART), aprotinin was withdrawn. We conducted a new meta-analysis
(including BART) on safety and efficacy of aprotinin in cardiac surgery.
Methods:We conducted a mixed treatment comparisons network meta-analysis estimating the effects of apro-
tinin and alternative agents in reducing blood loss during surgery. We implemented a combination of direct and
indirect evidence in mixed treatment comparisons and estimated relative effects for different agents on all-cause
mortality and return to the operating room for bleeding and conducted a supportive analysis of the effects of
different agents with only directly randomized trials.
Results:Mixed treatment analysis of 88 trials randomizing 15,528 patients to 1 of 3 antifibrinolytic agents dem-
onstrated no difference in mortality between placebo and antifibrinolytic agents. Analysis of aprotinin versus
tranexamic acid and ε-aminocaproic acid in 17 and 6 trials, respectively and tranexamic acid versus ε-amino-
caproic acid in 5 trials demonstrated no difference in mortality between treatment allocations. All agents
were superior to placebo in reducing reexploration for bleeding, with aprotinin numerically superior: aprotinin
odds ratio, 2.6 (95% confidence interval, 1.9-3.7); tranexamic acid odds ratio, 1.79 (1.2-2.9), and ε-aminocap-
roic acid odds ratio, 2.4 (1.3-6.6).
Conclusions: This mixed treatment comparisons meta-analysis demonstrates no increased mortality risk with
aprotinin versus other antifibrinolytic agents. All agents were superior to placebo in reducing reexploration
for bleeding after adult cardiac surgery. (J Thorac Cardiovasc Surg 2013;145:234-40)The age and risk profile of patients undergoing cardiac sur-
gery continue to increase.1 Such patients are at increased
risk for significant postoperative bleeding necessitating
transfusion of blood and blood products or further surgical
intervention.2,3 Although modern treatments have resulted
in similar early hospital mortalities between those who
have significant bleeding problems and those who have
not, this complication is still associated with significant
resource utilization and could affect adversely late
survival after surgery.3-5 Meta-analyses of antifibrinolytic
agents has shown that they reduce the incidence of clini-
cally significant bleeding, reducing both the need for trans-
fusion and the need for surgical reexploration.6
Blood transfusion itself is not a hazard-free intervention,
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The Journal of Thoracic and Cardiovascular Surgtransmission, acute lung injury necessitating prolonged venti-
lation, perioperative myocardial infarction, and altered im-
munity. Cardiac surgery accounts for a large proportion of
blood transfusion worldwide, almost 10% of all blood trans-
fusions.7 The importance of blood conservation in cardiac
surgery should therefore be considered, and at present the
use of antifibrinolytic drugs remains a key part of this strategy.
The serine protease inhibitor aprotinin was a commonly
used agent in this strategy, until the Blood Conservation
UsingAntifibrinolytics in aRandomizedTrial (BART) study8
was terminated early in response to concerns of increased
mortality associated with this agent. Since then, agents such
as tranexamic acid and ε-aminocaproic acid have now be-
come commonly used in blood conservation strategies in car-
diac surgery. These agents have limited safety data and their
use is not licensed in most countries.
BART has considerable design limitations, including the
lack of placebo control. These limitations have been
recently recognized by Health Canada (the department of
the government of Canada responsible for the national pub-
lic health) by reintroducing the use of aprotinin and calling
for further safety trials. More recently, the European Medi-
cine Agency has recommended the lifting of the restrictions
on the use of aprotinin.9 We conducted a mixed treatment
comparison (MTC) network meta-analysis to estimate the
effects of aprotinin and alternative agents in reducing bloodery c January 2013
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Mloss during surgery and to examine the safety profiles of
these agents.10
MATERIALS AND METHODS
Trials of aprotinin were identified and data were abstracted from the Co-
chrane meta-analysis by Henry and colleages.7 We conducted an MTC net-
work meta-analysis to estimate the effects of aprotinin and alternative
agents in reducing blood loss during surgery.10 There are two roles for
MTC analysis. The first is to strengthen inference concerning the relative
efficacies of a pair of treatments by including both ‘‘direct’’ and ‘‘indirect’’
comparisons. The other is to facilitate simultaneous inference regarding all
treatments, for example to select the best treatment.10 MTC and network
meta-analysis methods have becomewidely used in the evaluation of treat-
ments and form an important part of the work of organizations such as the
National Institute for Health and Clinical Excellence (NICE; http://www.
nicedsu.org.uk/), which actively promotes the use of MTC methods.
We estimated the relative effects for different agents on the outcomes of
all-cause mortality and return to the operating room for bleeding. We then
conducted a supportive analysis of the effects of different agents with only
the directly randomized trials and performed a number of analyses.
The first analysis was an MTC analysis of comparative trials that had an
active comparator. The second was an MTC analysis extended to all ran-
domized trials, including all placebo-controlled trials. The third compared
the effects of antifibrinolytic agents both with placebo and with each other
with respect to return to the operating room for bleeding. The lists of in-
cluded trials for the analysis of mortality and return to the operating
room for bleeding are provided in Tables 1 and 2, respectively.
RESULTS
The first analysis of comparative trials identified 17 trials
comparing aprotinin with tranexamic acid, 5 trials compar-
ing tranexamic acid with ε-aminocaproic acid, and 6 trials
comparing aprotinin with ε-aminocaproic acid, as shown
in Figure 1. The patient numbers for each treatment are
shown in Table 3. As shown in Figure 2, no differences in
mortality were demonstrated in this 3-way analysis, includ-
ing comparing aprotinin versus tranexamic acid (odds ratio
[OR], 0.83; 95% confidence interval [CI], 0.48-1.83).
The second analysis of patients randomly allocated to
treatment or control identified 88 trials. Figure 3 describes
the network of these, the majority (54/88) of which were be-
tween aprotinin and control. The overall patient numbers
analyzed are shown in Table 4, again with the greatest num-
ber being randomly allocated to aprotinin (n¼ 6284). Com-
paring all 3 agents with each other also demonstrated no
differences in mortality between groups, as shown in
Figure 4, including aprotinin versus tranexamic acid (OR,
0.73; 95% CI, 0.45-1.21) and aprotinin versus placebo
(OR, 1.11; 95% CI, 0.75-1.53).
The third analysis compared the 3 antifibrinolytic agents
with each other and with placebo, with respect to theThe Journal of Thoracic and Caoutcome of reexploration for bleeding, as shown in
Figure 5. All 3 agents were shown to be superior to placebo
in reducing reexploration for bleeding: aprotinin OR, 2.58
(95% CI, 1.91-3.70); tranexamic acid OR, 1.79 (95% CI,
1.22-2.91); and ε-aminocaproic acid OR, 2.4 (95% CI,
1.29-6.59). Aprotinin was shown to be numerically superior
to tranexamic acid in reducing reexploration for bleeding,
but this result was not statistically significant (aprotinin vs
tranexamic acid OR, 1.4; 95% CI, 0.94-2.08).
DISCUSSION
Aprotinin is the most studied antifibrinolytic agent for its
use in cardiac surgery, and this MTC meta-analysis, in
concordance with previous meta-analyses,7 supports the
contention that it is safe and very effective in preventing re-
exploration for hemorrhage and blood transfusions. MTC
analyses can provide useful estimates of treatment effects,
which are derived across a network of interlocking random-
ized trials. They are particularly useful in the context of in-
clusion of trials with different comparators, either placebo
or active therapies. Our MTC analysis advances the work
of Henry and colleagues,7 who included all relevant trials
but used only conventional direct meta-analysis to analyze
results. There have been several meta-analyses of random-
ized trials involving aprotinin. Levi and coworkers in
199911 demonstrated that aprotininwas associatedwith a re-
duction in mortality (OR, 0.55; 95% CI, 0.34-0.90), a 2001
Cochrane review12 demonstrated that the use of aprotinin
was not associated with increased mortality (OR, 0.87;
95% CI, 0.63-1.9), and the latter finding was confirmed
by Sedrakyan and associates13 in 2004 (OR, 0.96; 95%
CI, 0.65-1.4). Furthermore, aprotinin was associated with
a reduction in risk of stroke (OR, 0.53; 95% CI, 0.31-
0.90) and no increased mortality relative to other antifibri-
nolytic agents.13
Despite these findings, the issue of safety with the use of
aprotinin continued to be raised, particularly on the grounds
that the majority of the published trials were small, were fo-
cused on reduction in blood transfused or reoperation for
bleeding, and were not powered to detect a difference in
mortality.14 The meta-analysis of these trials demonstrated
significant and clinically important reductions in bleeding
and reoperation rate with aprotinin, so a further trial of
this agent versus placebo was not considered ethically jus-
tified.15 A further Cochrane review7 concluded that there
were insufficient data to recommend definitively any antifi-
brinolytic agent rather than another, and with the cost of
aprotinin being significantly greater than the other agents,
BART was conceived.8
BART and Its Aftermath
BARTwas powered to detect a 50% reduction (from 6%
to 3%) in massive bleeding (including reoperation) and
a 10% absolute risk reduction in allogeneic exposure tordiovascular Surgery c Volume 145, Number 1 235
TABLE 1. Trials included in the analysis for mortality
Study by first author Year
No. of patients
Aprotinin Control TXA EACA
Alderman* 1998 436 434
Alvarez* 1995 49 51
Alvarez* 2001 26 29
Andreasen* 2004 23 21
Armellin* 2001 150 150
Ashraf* 1997 19 19
Bernet* 1999 28 28
Bidstrup* 1989 40 40
Bidstrup* 1993 43 47
Bidstrup* 2000 30 30
Blauhut 1994 14 14 15
Brown* 1997 30 60
Casas* 1995 47 51
Casati* 1999 67 70 66
Casati* 2000 518 522
Cicekcioglu* 2006 20 24
Coffey 1995 14 16
Cohen 1998 56 59
Colwell 2007 175 178
Cosgrove* 1992 113 56
D’Ambra* 1996 141 71
Dalmau 2000 42 42
Dalmau* 2004 63 64
Del Rossi* 1989 180 170
Desai* 2009 38 37
Dietrich 1992 902 882
Dietrich* 1995 15 15
Dietrich* 2008 110 110
Dignan* 2001 101 99
Diprose* 2005 60 60 60
Dryden 1997 19 22
Englberger* 2002a 22 25
Englberger* 2002b 15 14
Feindt 1994 10 10
Fergusson* 2008 779 769 780
Golanski 2000 30 24
Gott 1998 109 112
Green 1995 48 36
Greilich 2009 26 27 25
Hardy* 1993 22 22
Hardy* 1998 45 43 46
Hayashida 1997 110 57
Hekmat 2004 60 58
Ickx 2006 24 27
Jamieson 1997 24 36
Jares* 2003 25 22
Jimenez* 2007 26 24
Karski 2005 165 147
Katoh 1997 31 62
Katsaros* 1996 106 104
Kipfer* 2003 15 15
Kluger* 2003 30 58
Koster* 2004 100 100
Kueppper* 2003 60 59
(Continued)
TABLE 1. Continued
Study by first author Year
No. of patients
Aprotinin Control TXA EACA
Kuitunen* 2005 20 20 20
Kunt* 2005 40 46
Landymore 1997 48 56 44
Lass* 1995 51 47
Later* 2009 96 103 99
Leijdekkers* 2006 16 19
Lemmer* 1996 526 178
Lemmer* 1994 108 108
Levy* 1995 215 72
Liu* 1993 20 20
Maccario 1994 61 32
Maddali* 2007 111 111
Mehr-Aein* 2007 33 33
Misfeld 1998 14 14 14
Mohr* 1992 34 16
Mongan* 1998 75 75
Moran* 2000 28 14
Murphy* 2006 50 50
Norman 2009 11 9
Nuttal* 2000 45 45 45
Rocha 1994 28 28
Rodrigus* 1996 46 47
Royston 1987 11 11
Santos* 2006 31 29
Schweizer* 2000 28 29
Shore-Lesserson* 1996 13 17
Stammers 1997 8 12
Swart 1994 49 49
Trinh-Duc 1992 29 27
Van der Linden 2005 37 38
Vander-Salm* 1996 50 51
Wei 2006 36 40
Wong* 2000 39 38
Zabeeda 2002 25 25
Sum 6284 4887 3048 1309
EACA, ε-Aminocaproic acid; TXA, tranexamic acid. *Marked studies are also in-
cluded in the analysis for reexploration for bleeding.
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Many blood products (from 50% to 40%) in patients treated
with aprotinin as compared with ε-aminocaproic acid or tra-
nexamic acid during high-risk cardiac surgical procedures.
BARTwas not designed or powered to assess mortality out-
come differences among the 3 agents. The study was termi-
nated prematurely in the wake of concerns of increased
mortality associated with aprotinin.
This study, however, had a number of important meth-
odologic limitations. The patient population was heteroge-
neous, because the trial enrolled patients undergoing
various operations, and often reoperations or procedures in-
cluding the aortic root and adult congenital heart procedures
that are known to carry differing operative risks. Despite
this overwhelming influence of procedure and patients char-
acteristics on mortality, there was no stratification ofery c January 2013
TABLE 2. Additional trials included in the analysis for reexploration
for bleeding
Study by first author Year
No. of patients
Aprotinin Control TXA EACA
Asimakopoulos 2000 8 10
Bennett-Guerrero 1997 99 105
Bert 2008 25 25
Bidstrup 1990 26 18
Boldt 1994 20 20
Casati 2004 50 52
Deleuze 1991 30 30
Demeyere 2006 20 20 20
Dietrich 1990 19 20
Hardy 1997 26 26
Horrow 1991 45 28
Karski 1995 100 50
Kuitunen 2006 15 15
Laub 1994 16 16
Mansour 2004 20 20 20
Menichetti 1996 24 24 24 24
Nurozler 2008 25 26
Parvizi 2007 81 81
Penta de Pepo 1995 15 15 15 15
Pleym 2003 39 40
Pugh 1995 25 15 25
Rao 1999 15 15
Ray 1997 21 23
Ray 1999 100 50
Ray 2001 49 51
Rossi 1997 21 24
Tabuchi 1994 20 20
Taggart 2003 36 34
Uozaki 2001 6 6
EACA, ε-Aminocaproic acid; TXA, tranexamic acid.
TABLE 3. Patient numbers for each treatment allocation in the
analysis of comparative trials
N Deaths
Aprotinin 2230 72
Tranexamic acid 2199 54
ε-Aminocaproic acid 1096 40
Howell et al Perioperative Managementtreatment allocation by procedure, patient risk profile, or
participating center. The investigators performed a logistic
regression adjustment for confounding factors, including
operative and comorbid conditions, but the results of thisFIGURE 1. Trials network diagram of the trials examined in the analysis
of comparative trials.
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Manalysis were not published. The reported mortality (not ad-
justed for procedure) in the aprotinin arm was 3.2% (25/
779), versus 1.3% (10/769) in the tranexamic acid arm
and 1.7% (13/780) in the ε-aminocaproic acid arm. Al-
though nominal ORs and CIs were calculated for these
groups, these do not allow for the repeated analyses that re-
duce the level of significance from the preset one (a spend-
ing), thus rendering the results statistically nonsignificant.
Health Canada has also reviewed BART again and, high-
lighting some irregularities in reclassification of primary
outcomes, has reissued guidance that the benefit of aproti-
nin outweighs the risk.16
After BART, a further retrospective database analysis
was conducted at the request of the manufacturer.17 It has
previously been demonstrated that retrospective analysis
of patients selectively treated with aprotinin is difficult to
perform, because aprotinin is typically used when a patient
is perceived to be at greater operative risk, a phenomenon
called ‘‘confounding by indication.’’ This confounding is
difficult to account for statistically, and the outcomes of
patients so selected to receive aprotinin thus may be per-
ceived as being inferior, a difference that has not been dem-
onstrated in patients treated in a nonselective manner.18
This large, observational study reflects such findings.
Patients in the aprotinin cohort were more than twice as
likely to have undergone reoperative surgery, and, although
this study was labeled as a study of patients undergoing
coronary artery bypass grafting, 25.2% of patients in the
aprotinin arm underwent concomitant valve surgery, com-
pared with 18% in the tranexamic acid group. Patients in
the aprotinin group were also older, had a greater incidence
of peripheral arterial disease, had a greater incidence of
chronic kidney disease, were more likely to undergo com-
plex coronary artery bypass grafting surgery, and
were more likely to have required treatment for heart
failure. Once the analysis took into account the surgeons’
selective bias with an instrumental variable analysis, no sig-
nificant adverse effect of aprotinin on survival was
demonstrated.
A further meta-analysis of 11 epidemiologic studies19
demonstrated no increase of in-hospital mortality with apro-
tinin but did show a reduced late survival. They also demon-
strated, however, that aprotinin was used with procedures
requiring a longer bypass time, which itself is a marker of
complex surgery and in this study was a predictor of adverse
events.rdiovascular Surgery c Volume 145, Number 1 237
FIGURE 2. Differences in mortality between treatments. Odds ratios are given, with 95% confidence intervals in parentheses. An odds ratio less than 1
favors the second listed treatment.
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MHistorical data suggest that reoperations for bleeding can
be associated with increased mortality.20 The issue has been
raised that the reduction in these complications seen with
aprotinin has not translated into improved survival. It is pos-
sible, however, that this is because more contemporary data
show similar early survivals for patients who have signifi-
cant bleeding and those who do not.3 Furthermore, more re-
cently, the withdrawal of aprotinin at the time when this
agent was thought to increase mortality has not resulted in
any improvement in early postoperative outcomes; rather,
there has been an increase in the use of blood products.21
Bleeding after cardiac surgery can be treated with surgicalFIGURE 3. Trials network diagram of all randomized trials contributing
to mortality analysis.
238 The Journal of Thoracic and Cardiovascular Surgreexploration and transfusion of blood and blood products,
and this inevitably leads to a significant increase in resource
requirement, especially of blood bank and critical care
resources, and may still result in late morbidity.
The story surrounding aprotinin may well have become
more interesting than the drug itself, and there are many les-
sons to be learned from this for all stakeholders. Investiga-
tors of new therapeutic agents, conducting several small
studies underpowered for mortality end points over a 30-
year period have not unequivocally demonstrated its safety,
and reports of early graft failure and renal impairment pre-
sumed to be secondary to the prothrombotic effects of anti-
fibrinolytic agents have not been adequately investigated.
Drug regulatory bodies have responded with knee-jerk reac-
tions to small, poorly designed trials and high-profile epide-
miologic studies, despite the significant weight of the
previous literature. Many patients have received aprotinin,
some of whom may have actually derived benefit from the
drug but nowmay either seek litigation or remain concerned
about their own outcomes. We have not seen any improve-
ments in clinical outcomes since the use of aprotinin has
been restricted, but there has been an increase in use ofTABLE 4. Patient numbers for each treatment and control in analysis
of all randomized trials
Agent Trials N Deaths
Aprotinin 67 6284 177
Tranexamic acid 35 3048 62
ε-Aminocaproic acid 11 1309 44
Placebo 75 4887 110
ery c January 2013
FIGURE 4. Comparison of active agents and placebo for the outcome of all-cause mortality. Odds ratios are given with 95% confidence intervals in
parentheses. An odds ratio less than 1 favors the second listed treatment.
Howell et al Perioperative Managementblood products.21 The patent for aprotinin has now expired
and it has now become another cheap generic drug. As such,
the appetite for running the large clinical safety trial that
should have been performed initially will now be lessened.
CONCLUSIONS
This meta-analysis, which includes data from BART,
demonstrates no increase in the risk of in-hospital mortalityFIGURE 5. Comparison of effects of different agents and placebo on the outco
95% confidence intervals in parentheses. An odds ratio less than 1 favors the s
The Journal of Thoracic and Cafor patients treated with aprotinin relative to either placebo
or other antifibrinolytic agents. This is in line with the
updated Cochrane review, which has also demonstrated no
increased risk of aprotinin relative to placebo and no in-
creased risks of myocardial infarction, stroke, and renal
dysfunction or failure. Most studies in our meta-analysis
include only patients undergoing coronary artery bypass
grafting. The evidence for higher-risk procedures is lackingme of return to the operating room for bleeding. Odds ratios are given with
econd listed treatment.
rdiovascular Surgery c Volume 145, Number 1 239
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Mfor all antifibrinolytic agents. Our analysis supports the
recent recommendations from Health Canada and the Euro-
pean Medicine Agency.References
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the post-aprotinin era. Circulation. 2011;124(11 Suppl):S62-9.TARYFacts, opinions, and conclusions: Aprotinin brings out all of theseVictor A. Ferraris, MD, PhDIn general, an opinion is a subjective belief, and is the result
of emotion or interpretation of facts. An opinion may besupported by an argument, although people draw opposing
opinions from the same set of facts. Almost all cardiac sur-
geons have an opinion about the use of aprotinin. These
opinions range from strong support for drug use to adamant
insistence that the drug causes harm. The facts that the sup-
porters and detractors use to form their opinions are the
same. Only conclusions differ.
WHATARE THE FACTS?
Fact 1: Aprotinin Reduces Bleeding, Blood
Transfusion, and Reoperation for Bleeding in
Patients Having a Variety of Cardiac Operations
There can be little doubt of this fact. In developing prac-
tice guidelines about blood conservation for the Society ofery c January 2013
